# Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

> **NCT01368081** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1162 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Metformin
- **DRUG:** BI 10773
- **DRUG:** Placebo (low dose)
- **DRUG:** BI 10773
- **DRUG:** Placebo (high dose)

## Key facts

- **NCT ID:** NCT01368081
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 1162 (ACTUAL)
- **Last updated:** 2014-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01368081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01368081, "Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01368081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*